Everest Detection — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Everest Detection is a private, pre-revenue diagnostics company targeting the transformative opportunity in early cancer detection. The company is building a technology platform informed by world-leading scientists and clinicians, though specific assay details and a clinical pipeline are not yet publicly disclosed. Its value proposition hinges on shifting diagnosis to earlier stages, where survival rates are significantly higher, particularly for deadly cancers like lung cancer.

Oncology

Technology Platform

Leveraging convergence of advances in molecular cancer biology and detection technologies including nucleotide sequencing, single-cell detection, microRNA, and proteomics for early cancer signal detection.

Opportunities

The global market for early cancer detection is massive and growing, driven by the dramatic improvement in survival rates and healthcare cost savings when cancer is caught early.

Advances in sequencing and molecular analysis now provide the technical foundation to detect cancer signals before traditional methods.

Risk Factors

The company faces significant technical risk in developing a test with the required sensitivity and specificity, intense competition from well-funded rivals, and the long, costly path to regulatory approval and insurance reimbursement.

As a pre-revenue startup, it is also dependent on securing ongoing funding.

Competitive Landscape

The multi-cancer and single-cancer early detection space is highly competitive, featuring well-capitalized players like GRAIL (Illumina), Exact Sciences, and Freenome, as well as large diagnostic conglomerates. Everest must differentiate its technology on performance, cost, or specific cancer focus to succeed.

More companies in Diagnostics & Precision Medicine →More companies in United States →